The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2006Roles of Parkin/PINK1/DJ-1 Complex in Parkinson's Disease Pathogenesis
Mutations in at least six genes, including alpha-synuclein, uchL1, LRRK2, parkin, PINK1, and DJ-1, are linked to Parkinson's disease. One vital question is how mutations in six different genes...
-
Therapeutics Development Initiative, 2006Small molecule TNF-alpha inhibitors as neuroprotectant drugs for PD
Several preclinical and clinical studies implicate the neuroinflammatory cytokine TNF-alpha as a key mediator in PD-associated neurodegenerative pathology. P2D, Inc. has recently identified four lead...
-
Therapeutics Development Initiative, 2006Development of a biodegradable delivery matrix containing dopaminergic neurons derived from clinical grade mesencephalic stem cell lines for the treatment of Parkinson’s disease
The movement disorder seen in Parkinson's disease arises from the loss of dopamine-producing, or dopaminergic, neurons. Regenerative medicine using stem cell therapy provides renewed hope for patients...
-
Therapeutics Development Initiative, 2006Evaluation of the Neuroprotective Peptide NAPVSIPQ in Models of Parkinson's Disease
Parkinson's disease is characterized by the selective loss of dopamine neurons, which leads to reduced control of voluntary locomotor activities. The cause of this degeneration is unknown; however...
-
Therapeutics Development Initiative, 2006Development of Disease Modifying Therapeutic for Parkinson's Disease
Parkinson's Disease is a devastating neurological disorder for which there is no known cure. Our goal is to develop drug candidates to slow or halt the progression of PD. This will be done by focusing...
-
Therapeutics Development Initiative, 2006Neuroprotective Effects of A2A Antagonists in Rodent Models of Motor Function and Dyskinesia
The principal feature of Parkinson's disease is a progressive death of dopamine neurons in the substantia nigra. Pharmacological therapies that enhance dopamine activity effectively treat the rigidity...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.